Revisiting IBD Management: Dogmas to be Challenged

September 30 – October 1, 2011
Sheraton Brussels Hotel
Belgium
CME credits for the Falk Symposium 179 have been applied for at the European Union of Medical Specialists (UEMS) – European Board of Gastroenterology (EBG). The number of credits awarded will be printed in the final program.
Preface

The field of inflammatory bowel disease is rapidly evolving. Our knowledge of genetic predisposition, immunological mechanisms and disease behaviour has never expanded as widely as in the last decade. Our tools to accurately visualize the extent and severity of inflammation and to detect dysplasia and cancer have become highly reliable. The list of novel small molecules and biologic agents targeting various mechanisms in the inflammatory cascade and in the vascular adhesion system is virtually endless. Yet, many relevant questions remain unanswered when it comes to daily IBD management.

What is the optimal target for disease control? Why does IBD often ‘escape’ despite a time window of successful response to certain treatments? Why does the disease behaviour sometimes change drastically during the disease course? Why is postoperative recurrence of Crohn’s disease virtually inevitable?

Although we have been convinced that we had found many answers to these questions, we need to realize that many such ‘dogmas’ need to be questioned and readdressed. The 106th FALK symposium wishes to contribute to this critical attitude vis à vis ‘ancient beliefs’ in the field of IBD. The era of evidence based medicine forces us to critically review scientific data, to rephrase certain standards and, above all, to translate novel insights into the daily care for our patients.

As scientific organizers of this symposium, we hope that you will join us on this exciting scientific and clinical journey through the world of IBD. We hope to go home with a clearer view of the intriguing enigma that is IBD.

Geert D’Haens MD, PhD
Also on behalf of Severine Vermeire and Axel Dignass
Revisiting IBD Management: Dogmas to be Challenged

Sheraton Brussels Hotel
Belgium

Registration:
Thursday September 29, 2011
16.00 – 21.00 h
at the congress office

Information:
Prof. Dr. Geert D’Haens
Academic Medical Centre
Department of Gastroenterology
Meibergdreef 9
1105 AZ Amsterdam
The Netherlands
Telephone: +31(0)20/5 66 41 09
Telefax: +31(0)20/6 91 70 33
E-Mail: gdhaens@amc.uva.nl

Official Language:
English

Call for posters:
For details see page 11

Publication date of final program:
September 2011

The final program will be available on the homepage www.falkfoundation.org one week before.
Friday, September 30, 2011

9.00 Welcome

Dogma 1 – IBD is a disorder of defective autophagy and innate immunity

Chair: S. Danese, Rozzano; J. Satsangi, Edinburgh

9.05 Introduction

9.10 Evidence from genetics for the role of autophagy and innate immunity in pathogenesis of IBD

9.40 Bacterial interactions with innate mucosal immunity

10.05 Endoplasmatic reticulum stress and inflammation

10.30 How can innate immunity be stimulated or “corrected”?  

10.55 Wrap-up

11.00 Coffee break with poster session

Dogma 2 – No bacteria, no IBD

Chair: A. Darfeuille-Michaud, Clermont-Ferrand; W. M. de Vos, Wageningen

11.20 Introduction

11.25 Lessons from diversion studies and antibacterial interventions

11.45 Pouchitis and the role of bacteria in prevention and treatment of IBD

12.05 The role of anti(myco)bacterial interventions in the current management of IBD: Is there evidence at all?

12.30 The gut microbiome in health and IBD: Targets for the future?

12.55 Wrap-up

13.00 Lunch break with poster session
Friday, September 30, 2011

Dogma 3 – TNF plays a pivotal role in IBD

Chair: P. Rutgeerts, Leuven; H. Tilg, Innsbruck

14.00 Introduction

14.05 Is efficacy of anti-TNF therapy really related to neutralisation of TNF and apoptosis?

14.30 Mechanisms of relapse and loss of response to anti-TNF treatment

14.55 Anti-TNF therapy in CD and UC: Similar diseases, similar efficacy?

15.15 Therapeutic alternatives after failure of anti-TNF treatment for IBD

15.35 Wrap-up

15.40 Coffee break with poster session

Dogma 4 – Steroids are useful for the management of IBD

Chair: G. D’Haens, Amsterdam; S. B. Hanauer, Chicago

16.00 Introduction

16.05 Do steroids have an adverse effect on IBD outcome and healing?

16.25 Pathophysiological changes during steroid treatment for IBD

16.50 Steroids with biologicals: Allies or enemies?

17.15 Novel steroid formulations: Higher efficacy, less toxicity?

17.40 Wrap-up

17.45 End of afternoon session
Saturday, October 1, 2011

**Dogma 5 – Early and late Crohn’s disease are distinct entities**

**Chair:** G. Mantzaris, Athens; C. J. van der Woude, Rotterdam

8.30  Introduction

8.35  Epidemiology of transition from early to late Crohn’s disease

8.55  Markers that differentiate early from late IBD

9.20  Can fibrosis be prevented in Crohn’s disease?

9.45  Can we slow down evolution from early to late CD?

10.10  Wrap-up

10.15  **Coffee break with poster session**

**Dogma 6 – Innovative treatments will offer a better outcome for patients with IBD**

**Chair:** S. Schreiber, Kiel; S. P. L. Travis, Oxford

10.45  Introduction

10.50  Biologic therapies: Lessons from MS

11.15  Current status of mesenchymal stem cell and bone marrow transplantation in IBD

11.35  Resetting the mucosal immune system: Dream or reality?

12.00  Old wine in new bags: 5-ASA revisited?

12.25  Wrap-up

12.30  **Lunch break with poster session**
**Saturday, October 1, 2011**

**13.30** Presentation of Poster Prizes

**Scientific Committee**

**Dogma 7 – Patient tailored therapies are superior to algorithmic approaches in IBD**

**Chair:** F. Baert, Roeselare; B. G. Feagan, London (ON)

**13.40** Introduction

F. Baert, Roeselare

**13.45** Predicting the disease course from diagnosis

J. Panés, Barcelona

**14.10** How to guide therapeutic decisions in a patient-tailored approach?

P. Rutgeerts, Leuven

**14.35** Pharmacogenetics and prediction of therapy success

D. McGovern, Los Angeles

**15.00** Approach to IBD: Treating the disease or the patient? How I do it.

S. B. Hanauer, Chicago

**15.20** Wrap-up

B. G. Feagan, London (ON)

**15.25** Coffee break with poster session

**Dogma 8 – Immunosuppression puts IBD patients at risk for severe complications**

**Chair:** J.-F. Colombel, Lille; D. Franchimont, Brussels

**15.55** Introduction

D. Franchimont, Brussels

**16.00** Combined immunosuppression is more dangerous than monotherapy: What is fact and what is rumor

J. Schölmerich, Frankfurt

**16.20** Prevention and management of infectious complications in IBD

J. F. Rahier, Yvoir

**16.40** Lymphoma and cancer in IBD: Can they be prevented?

L. Beaugerie, Paris

**17.00** How to manage IBD in patients with infections or malignancies?

A. Kohn, Rome

**17.20** Wrap-up

J.-F. Colombel, Lille
Wrap-up session
Leaving the dogmas behind and looking into the future

Chair: M. de Vos, Gent; R. Panaccione, Calgary

17.25 Towards a novel molecular classification of IBD
S. Vermeire, Leuven

17.40 Towards objective disease measurement
M. de Vos, Gent

17.55 Towards individualized therapeutic approaches in IBD
G. D’Haens, Amsterdam

18.10 Toward a “cure” for IBD
C. Fiocchi, Cleveland

18.30 Discussion

18.40 End of meeting
Poster Session

Posters will be exhibited on September 30 and October 1, 2011, at the Sheraton Brussels Hotel. The authors will be in attendance during coffee and lunch breaks on both days.

Call for posters

Please submit your poster abstract before May 15, 2011. Only one-page abstracts not exceeding 250 words, written in English and saved in Microsoft Word format will be accepted.

Abstracts must be submitted via our Internet Abstract Submission System (http://www.falkfoundation.com/poster) where further information regarding the submission format and the submission process is available.

The abstracts will be selected by the scientific organizers, preference being given to those thematically related to one of the sessions of the program.

The accepted abstracts will be printed and distributed to the participants of the congress together with the documents of the meeting.

The authors will receive notification about acceptance and further instructions in June 2011.

Contact address for further information on the poster session:

Falk Foundation e.V.
P.O. Box 6529
79041 Freiburg/Germany
Telephone: +49 (0) 761 / 15 14 - 0
Telefax: +49 (0) 761 / 15 14 - 359
Web address for submitting poster abstracts:
http://www.falkfoundation.com/poster

For the first author of an accepted poster, expenses for accommodation (September 29 – October 2, 2011) and fees for the scientific program and evening activities will be covered during the Falk Symposium 179.

Travel expenses are not covered.

Poster prizes

Three prizes will be awarded for the best presentations. Prize winners will be presented with a prize certificate and cheques for € 1.500,-, € 1.000,- and € 500,- respectively. Travel expenses will be covered additionally for the first author of prize winning posters.
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Address</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Matthieu Allez</td>
<td>Hôpital Saint-Louis</td>
<td>1 Ave. C. Vellefaux 75010 Paris, France</td>
<td><a href="mailto:matthieu.allez@sls.aphp.fr">matthieu.allez@sls.aphp.fr</a></td>
</tr>
<tr>
<td>Dr. Filip Baert</td>
<td>Heilig Hart Ziekenhuis</td>
<td>Wilgenstraat 2, 8800 Roeselare, Belgium</td>
<td><a href="mailto:fbaert@hhr.be">fbaert@hhr.be</a></td>
</tr>
<tr>
<td>Dr. Laurent Beaugerie</td>
<td>Hôpital Saint Antoine</td>
<td>184, Rue du Faubourg St.-Antoine, 75571 Paris, France</td>
<td><a href="mailto:laurent.beaugerie@sat.aphp.fr">laurent.beaugerie@sat.aphp.fr</a></td>
</tr>
<tr>
<td>Prof. Dr. Elke Cario</td>
<td>Gastroenterologische Laboratorien</td>
<td>Universitätsklinikum Essen, Virchowstr. 179, 45147 Essen, Germany</td>
<td><a href="mailto:elke.cario@uni-due.de">elke.cario@uni-due.de</a></td>
</tr>
<tr>
<td>Dr. Yehuda Chowers</td>
<td>Chaim Sheba Medical Center</td>
<td>2 Sheba Road, 52 621 Tel Hashomer, Israel</td>
<td><a href="mailto:ychowers@post.tau.ac.il">ychowers@post.tau.ac.il</a></td>
</tr>
<tr>
<td>Prof. Dr. Jean-Frederic Colombel</td>
<td>Hôpital Claude Huriez</td>
<td>1, Place de Verdun, 59037 Lille, France</td>
<td><a href="mailto:jfcolombel@chru-lille.fr">jfcolombel@chru-lille.fr</a></td>
</tr>
<tr>
<td>Dr. Silvio Danese</td>
<td>Istituto Clinico Humanitas</td>
<td>Via Manzoni, 56, 20089 Rozzano, Italy</td>
<td>s <a href="mailto:danese@hotmail.com">danese@hotmail.com</a></td>
</tr>
<tr>
<td>Dr. Arlette Darfeuille-Michaud</td>
<td>Université d’Auvergne</td>
<td>CBRV, Laboratoire de Bactériologie</td>
<td><a href="mailto:arlette.darfeuille-michaud@u.clermont1.fr">arlette.darfeuille-michaud@u.clermont1.fr</a></td>
</tr>
<tr>
<td>Prof. Dr. Martine de Vos</td>
<td>Rijksuniversiteit Gent</td>
<td>Universitair Ziekenhuis, Gastro-entérologie</td>
<td><a href="mailto:martine.devos@rug.ac.be">martine.devos@rug.ac.be</a></td>
</tr>
<tr>
<td>Prof. Dr. Willem M. de Vos</td>
<td>Wageningen University</td>
<td>Laboratory of Microbiology</td>
<td><a href="mailto:willem.devos@wur.nl">willem.devos@wur.nl</a></td>
</tr>
<tr>
<td>Dr. Geert D’Haens</td>
<td>Academic Medical Center</td>
<td>Department of Gastroenterology</td>
<td><a href="mailto:gdhaens@amc.uva.nl">gdhaens@amc.uva.nl</a></td>
</tr>
</tbody>
</table>
Prof. Dr. Paul Rutgeerts
University Ziekenhuis
Gasthuisberg
Gastro-entérologie
Herestraat 49
3000 Leuven
Belgium
paul.rutgeerts@uz.kuleuven.ac.be

Dr. Miquel Sans Cufí
Hospital Clínic y Provincial
Universidad de Barcelona
Inflammatory Bowel Disease Unit
c/ Villarroel no. 170
08036 Barcelona
Spain
msans@clinic.ub.es

Prof. Dr. Jack Satsangi
University of Edinburgh
Western General Hospital
Gastrointestinal Unit
Crewe Road
Edinburgh EH4 2XU
Great Britain
j.satsangi@ed.ac.uk

Prof. Dr. Jürgen Schölmerich
Klinikum der Johann Wolfgang
Goethe-Universität Frankfurt
Theodor-Stern-Kai 7
60596 Frankfurt
Germany
juergen.schoelmerich@kgu.de

Prof. Dr. Stefan Schreiber
Innere Medizin I
Universitätsklinikum
Schleswig-Holstein, Campus Kiel
Schittenhelmstr. 12
24105 Kiel
Germany
s.schreiber@1med.uni-kiel.de

Bo Shen, M.D.
The Cleveland Clinic Foundation
Gastroenterology & Hepatology
Mail Code A30
9500 Euclid Avenue
Cleveland OH 44195
USA
shenb@ccf.org

Prof. Dr. Herbert Tilg
Bezirkskrankenhaus
Hall i.T.
Interne Abt.
Milserstr. 10
6060 Hall / Tirol
Austria
herbert.tilg@i-med.ac.at

Dr. Simon P.L. Travis
John Radcliffe Hospital
NHS Trust
Department of Gastroenterology
Headley Way Headington
Oxford OX3 9DU
Great Britain
simon.travis@ndm.ox.ac.uk

Prof. Dr. Gert van Assche
University Ziekenhuis
Gasthuisberg
Gastro-entérologie
Herestraat 49
3000 Leuven
Belgium
gert.vanassche@uz.kuleuven.ac.be

Dr. G. R. van den Brink
Univ. van Amsterdam, Tytgat Inst
for Liver & Intestinal Research
Laboratory of Experimental
Medicine, Room G2-130
Meibergdreef 9
1105 AZ Amsterdam
Netherlands
g.r.vandenbrink@amc.uva.nl
General Information

Prior to the opening of the congress in Brussels

Falk Foundation e. V.                                             Telephone: +49 (0) 761 / 15 14 - 0
Congress Division                                                Telefax:    +49 (0) 761 / 15 14 - 359
Leinenweberstr. 5                                               E-mail:    symposia@falkfoundation.de
P.O. Box 6529                                                   
79041 Freiburg/Br. (Germany)

Congress Office

During the Falk Symposium 179

Sheraton Brussels Hotel                                         Telephone: +32 (0) 2 / 224 38 01
Place Rogier 3                                                  Telefax:    +32 (0) 2 / 224 30 01
1210 Brussels                                                  Belgium

Opening Hours:
Thursday, September 29, 2011  16.00 – 21.00 h
Friday, September 30, 2011    8.00 – 18.00 h
Saturday, October 1, 2011     8.00 – 18.40 h

Congress Fees

Scientific program of the Falk Symposium 179                   € 200,-
Students and residents                                        € 100,-

* * * OR * * *

Day ticket                                                     € 120,-
Students and residents                                        € 60,-

The congress fees include:
- Welcome Evening on September 29, 2011
- Refreshments during coffee breaks
- Lunch on September 30 and October 1, 2011
- A copy of the abstract volume
Registration

Congress registrations must reach the Falk Foundation e.V. by **July 31, 2011 at the latest.** Congress fees may be paid by cheque payable to the Falk Foundation e.V. or by bank transfer to Volksbank Freiburg e.G., Germany, Bank No. 68090000, Account No. 1452010, IBAN DE33 6809 0000 0001 4520 10, BIC Genode 61 FR1. Please mark bank transfers with „Falk Symposium 179“.

To ensure correct registration, participants are asked to send in their registration and the fee remittance together.

After receipt of registration form, each participant will be provided with confirmation of his registration. On presentation of this confirmation at the Congress Office in Brussels participants will receive the congress folder containing name badges, admission tickets and the abstract volume.

In the event of registration cancellations, a handling fee of EUR 20,- will be deducted from the refund. All participants will receive a written confirmation of attendance at the end of the meeting.

Admission to Scientific Events

For admission to scientific events your name badge should be clearly visible.

Hotel Accommodation

Hotel reservations can be made online:
www.booking.com/hotels

Congress Report

The official congress report of the Falk Symposium 179 “Revisiting IBD Management: Dogmas to be Challenged” will be published in English in the first half of 2012 by Karger Publishers, Basel, Switzerland. Orders for this book at a reduced subscription price of € 35.- can be placed at the Congress Office during the congress in Brussels.

Congress Short Report

The congress short report of the Falk Symposium 179 will be published by the Falk Foundation e.V. with number FSK 179 in the first half on 2012.

Orders for this short report, free of charge, can be placed with the Falk Foundation e.V.

Airport

International Airport Brussels
Innovative Drugs
for bowel and liver diseases
Modern formulations and specially designed delivery systems ensure targeted release of the active drug

Scientific Dialogue
in the interest of therapeutic progress
Falk Symposia and Workshops
nearly 250, attended by more than 100,000 participants from over 100 countries since 1967
Continuing medical education seminars
over 14,000, attended by more than one million physicians and patients in Germany alone
Comprehensive literature service for healthcare professionals and patients
with more than 200 publications

www.falkfoundation.org  www.drfalkpharma.com
General Information:

FALK FOUNDATION e.V.
Leinenweberstr. 5
79108 Freiburg
Germany

Congress Division
Telephone: +49(0)761/1514-0
Telefax: +49(0)761/1514-359
E-mail: symposia@falkfoundation.de
www.falkfoundation.org